Like this article?
Get your free daily medical news from Physician's First Watch.
Featured in Journal Watch: Low-Dose Thrombolysis Improves Outcomes in Submassive Pulmonary Embolism
By The Journal Watch Editors
Low-dose tissue plasminogen activator (TPA) is safe and effective for treating moderate-sized pulmonary embolism (PE), according to a small prospective, randomized trial in the American Journal of Cardiology.
Researchers randomized 121 adults with symptomatic moderate PE to receive "safe dose" TPA (50 mg administered as a 10-mg bolus followed by a 40-mg infusion within 2 hours) plus anticoagulation with heparin or enoxaparin (thrombolysis group) or anticoagulation alone (control group). At a mean follow-up of 28 months, pulmonary hypertension was present in 16% of the thrombolysis group and 57% of the control group, and the composite endpoint of pulmonary hypertension and recurrent PE occurred in 16% and 63% of patients, respectively.
Published in Physician's First Watch February 5, 2013
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.